OBIO CAAP Company: Flosonics Medical Secures $5 Million Seed Round Funding

Sudbury-based FloSonics Medical has raised $5 million in funding led by iGan Partners.Other investors include Genesys Capital, MaRS Investment Accelerator Fund (IAF), Accel-RX, MaRS Catalyst, Angel One, and Northern Ontario Angels.

We’re very enthusiastic about the investors who partnered in the current financing round lead by iGan Partners. It marks a critical step in the commercial development of our proprietary FloPatch technology. Our company is developing a non-invasive means of monitoring critically ill patients during the early stages of shock inside and outside the hospital
— Joe Eibl, CEO, co-founder, FloSonics Medical
Previous
Previous

OBIO CAAP Company: Biotagenics Partners with University of Ottawa and CHEO on $9.1 Million Project with Genome Canada to Develop Therapies for Inflammatory Bowel Disease

Next
Next

OBIO CAAP Company: Mariner Endosurgery Receives Health Canada Investigational Testing Approval for LaparoGuard Technology